%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
uuid:13da0695-d1b3-b842-bca3-a212ada50944
adobe:docid:indd:fcd0f0d8-35d9-11dc-981d-b22758418c4c
xmp.id:D532D6C2072068118C148EC91461DD9D
proof:pdf
xmp.iid:86A04CB5452068118083E96140DE96F7
xmp.did:8CD44F683E2068118083AC285B7C0F5B
adobe:docid:indd:fcd0f0d8-35d9-11dc-981d-b22758418c4c
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2015-07-01T08:38:06+02:00
2015-07-01T08:38:06+02:00
2015-07-01T08:38:07+02:00
2015-07-01T08:38:07+02:00
Adobe InDesign CS6 (Macintosh)
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
8 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 566.929 765.354]/Type/Page>>
endobj
37 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
10 0 0 10 514.4882 697.6063 Tm
(191)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
0 1 0 0 k
/GS0 gs
/C2_0 1 Tf
10 0 0 10 56.6929 645.6459 Tm
<0051>Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.378 Tw /Span<>> BDC
( )Tj
EMC
(REFEREN)Tj
/Span<>> BDC
(C)Tj
EMC
(ES)Tj
/T1_2 1 Tf
0.069 Tw 9 0 0 9 56.6929 627.1459 Tm
[([1] Sobottke R., Zar)18(ghooni K., Kr)18(engel M., et al. T)90(r)18(eat)]TJ
0 Tw (-)Tj
0.055 Tw 0 -1.167 TD
(ment of spondylodiscitis in human immunodeficiency )Tj
0.178 Tw 0 -1.167 TD
[(vir)8(us-infected patients: a comparison of conservative )]TJ
0 Tw 0 -1.167 TD
[(and operative therapy)111.2(. )]TJ
/T1_3 1 Tf
(Spine)Tj
/T1_2 1 Tf
( 34,)Tj
/T1_4 1 Tf
( )Tj
/T1_2 1 Tf
(E452-E458, 2009.)Tj
0.06 Tw T*
[([2] Siewe J., Oppermann J., Eysel P)129(., Zar)18(ghooni K., So)]TJ
0 Tw (-)Tj
0.092 Tw 0 -1.167 TD
[(bottke R. Diagnosis and tr)18.1(eatment of spondylodiscitis )]TJ
0.031 Tw 0 -1.167 TD
[(in HIV)74.1(-positive patients. )]TJ
/T1_3 1 Tf
(Acta Orthop. Belg.)Tj
/T1_2 1 Tf
( 79, 475-482, )Tj
0 Tw T*
(2013.)Tj
0.104 Tw 0 -1.167 TD
[([3] Cottle L., Rior)18(dan T)74(. Infectious spondylodiscitis. )]TJ
/T1_3 1 Tf
0 Tw (J. )Tj
0 -1.167 TD
(Infect)Tj
/T1_2 1 Tf
(. 56, 401-412, 2008.)Tj
0.039 Tw T*
[( [4] Lewden C., May T)74(., Rosenthal E., et al. Changes in )]TJ
-0.012 Tw 0 -1.167 TD
(causes of death among adults infected by HIV between )Tj
0.085 Tw 0 -1.167 TD
(2000 and 2005: the \223Mortalit\351 2000 and 2005\224 surveys )Tj
0.185 Tw T*
(\(ANRS EN19 and Mortavic\). )Tj
/T1_3 1 Tf
[(J. )0.5(Acquir)74(. Immune Defic. )]TJ
0 Tw 0 -1.167 TD
(Syndr)Tj
/T1_2 1 Tf
(. 48, 590-598, 2008.)Tj
0.01 Tw 0 -1.167 TD
[([5] Palella F)92(.J. Jr)74(, Baker R.K., Moorman )37.2(A.C., et al. Mor)]TJ
0 Tw 23.919 0 Td
(-)Tj
0.226 Tw -23.919 -1.167 Td
[(tality in the highly active antir)18(etr)18(oviral therapy era: )]TJ
0.089 Tw 0 -1.167 TD
(changing causes of death and disease in the HIV out)Tj
0 Tw (-)Tj
0.07 Tw 0 -1.167 TD
[(patient study)111(. )]TJ
/T1_3 1 Tf
[(J. Acquir)74(. Immune Defic. Syndr)]TJ
/T1_2 1 Tf
(. 43, 27-34, )Tj
0 Tw T*
(2006.)Tj
0.098 Tw 0 -1.167 TD
[([6] MacDonald D.C., Nelson M., Bower M., Powles T)74(. )]TJ
0.22 Tw 0 -1.167 TD
[(Hepatocellular car)18.1(cinoma, human immunodeficiency )]TJ
0.172 Tw T*
[(vir)8(us )0.6(and )0.5(viral )0.6(hepatitis )0.6(in )0.5(the )0.6(HAAR)37(T )0.5(era. )]TJ
/T1_3 1 Tf
20.713 0 Td
[(W)20(orld )0.6(J. )]TJ
0 Tw -20.713 -1.167 Td
[(Gastr)18(oenter)18.1(ol. )]TJ
/T1_2 1 Tf
(14,1657-1663, 2008.)Tj
0.067 Tw T*
[([7] )0.5(Rosenthal )0.6(E., )0.6(Poir)18(ee )0.6(M., )0.5(Pradier )0.6(C., )0.5(et )0.5(al. )0.6(Mortality )]TJ
0.123 Tw T*
[(due to hepatitis C-r)18(elated liver disease in HIV infect)]TJ
0 Tw (-)Tj
0.09 Tw 0 -1.167 TD
[(ed )0.5(patients )0.5(in )0.5(France )0.5(\(Mortavic )0.6(2001 study\). )]TJ
/T1_3 1 Tf
0 Tw 20.273 0 Td
(AIDS)Tj
/T1_2 1 Tf
0.09 Tw [( )0.5(17, )]TJ
0 Tw -20.273 -1.167 Td
(1803-1809, 2003.)Tj
0.091 Tw 0 -1.167 TD
[([8] Gior)18(dano )0.5(T)74(.P)129(., Kramer J.R., Souchek )0.5(J., Richar)18(dson )]TJ
0.095 Tw 0 -1.167 TD
[(P)129(., )0.5(El-Serag H.B. )0.5(Cirr)18(hosis )0.5(and )0.5(hepatocellular )0.6(car)18(cino)]TJ
0 Tw (-)Tj
-0.008 Tw 0 -1.167 TD
[(ma in HIV)74(-infected veterans with and without the hep)]TJ
0 Tw (-)Tj
0.154 Tw T*
[(atitis )0.5(C )0.5(vir)8(us: )0.5(a )0.5(cohort )0.6(study)111(, )0.5(1992-2001. )]TJ
/T1_3 1 Tf
18.792 0 Td
[(Ar)18(ch. )0.5(Intern. )]TJ
0 Tw -18.792 -1.167 Td
(Med)Tj
/T1_2 1 Tf
(. 164, 2349-2354, 2004.)Tj
0.078 Tw T*
[([9] Di Benedetto N.,\037)-77.6(Peralta )0.5(M.,\037)-77.7(Alvar)18(ez E.,\037)-77.6(et al. Inci)]TJ
0 Tw (-)Tj
0.184 Tw T*
[(dence of hepatocellular car)18(cinoma in hepatitis C cir)]TJ
0 Tw 23.919 0 Td
(-)Tj
0.136 Tw 2.223 41.856 Td
[(r)18(hotic patients with and without HIV infection: )0.5(a co)]TJ
0 Tw (-)Tj
T*
[(hort study)111.1(, 1999-201)55(1. )]TJ
/T1_3 1 Tf
(Ann. Hepatol.)Tj
/T1_2 1 Tf
(\03713\(1\), 38-44, 2013.)Tj
0.042 Tw T*
[( [10] Kramer J.R.,\037)-41.8(Kowalkowski M.A.,\037)-41.8(Duan Z.,\037)-41.8(Chiaio )]TJ
0.183 Tw 0 -1.167 TD
[(E.Y)111(. The ef)18(fect )0.5(of\037)-182.6(HIV\037)-182.6(viral )0.5(contr)18(ol )0.5(on the incidence )]TJ
0.084 Tw 0 -1.167 TD
[(of\037)-83.7(hepatocellular car)18(cinoma\037)-83.7(in veterans with hepatitis )]TJ
0.094 Tw T*
[(C and\037)-93.8(HIV\037)-93.7(coinfection. )]TJ
/T1_3 1 Tf
[(J. Acquir)74(. Immune Defic. Syndr)]TJ
/T1_2 1 Tf
0 Tw (. )Tj
0 -1.167 TD
(68\(4\), 456-462, 2015.)Tj
0.07 Tw 0 -1.167 TD
[([1)55(1] Puoti M., Br)8(uno R., Soriano V)129(., et al. Hepatocellu)]TJ
0 Tw (-)Tj
-0.039 Tw T*
[(lar )0.5(car)17.9(cinoma )0.5(in )0.6(HIV)74(-infected )0.6(patients: )0.6(epidemiological )]TJ
0.154 Tw 0 -1.167 TD
[(featur)18(es, clinical pr)18(esentation and outcome. )]TJ
/T1_3 1 Tf
0 Tw (AIDS)Tj
/T1_2 1 Tf
0.154 Tw ( 18, )Tj
0 Tw 0 -1.167 TD
(2285-2293, 2004.)Tj
0.031 Tw T*
[([12] Ber)18.1(enguer J., )37.2(Alvar)18.1(ez-Pellicer J., Mart\355n P)129(.M., et al. )]TJ
0.091 Tw 0 -1.167 TD
[(Sustained vir)18(ological r)18(esponse to interfer)18(on plus riba)]TJ
0 Tw (-)Tj
0.017 Tw 0 -1.167 TD
[(virin r)18(educes liver)18.1(-r)18(elated complications and mortality )]TJ
0.117 Tw T*
(in patients coinfected with human immunodeficiency )Tj
-0.057 Tw 0 -1.167 TD
[(vir)8(us and hepatitis C vir)8(us. )]TJ
/T1_3 1 Tf
0 Tw (Hepatology)Tj
/T1_2 1 Tf
-0.057 Tw ( 50, 407-413, 2009.)Tj
0.033 Tw 0 -1.167 TD
([13] Sulkowski M.S., Naggie S., Lalezari J., et al. Sofos)Tj
0 Tw (-)Tj
-0.01 Tw T*
(buvir and ribavirin for hepatitis C in patients with HIV )Tj
0 Tw 0 -1.167 TD
(coinfection. )Tj
/T1_3 1 Tf
(JAMA)Tj
/T1_2 1 Tf
( 312\(4\), 353-361, 2014. )Tj
0.143 Tw 0 -1.167 TD
([14] Lawitz E., Sulkowski M.S., Ghalib R., et al. Sim)Tj
0 Tw (-)Tj
0.153 Tw T*
[(epr)18(evir plus sofosbuvir)74.1(, with or without ribavirin, to )]TJ
0.057 Tw 0 -1.167 TD
[(tr)18(eat chr)18(onic infection with hepatitis C vir)8.1(us genotype )]TJ
0.106 Tw 0 -1.167 TD
[(1 in non-r)18(esponders to pegylated interfer)18.1(on and riba)]TJ
0 Tw (-)Tj
0.109 Tw T*
[(virin and tr)18(eatment-naive patients: the COSMOS ran)]TJ
0 Tw (-)Tj
0 -1.167 TD
[(domised study)111.1(. )]TJ
/T1_3 1 Tf
(Lancet)Tj
/T1_2 1 Tf
( 384, 1756-1765, 2014.)Tj
-0.01 Tc -0.085 Tw 0 -1.167 TD
[([15] Zeuzem S., Hezode C., Br)18(onowicki J.P)129(.P)129(., \(LEAGUE-1)-10( )]TJ
-0.033 Tw T*
[(Study T)92(eam\). Daclatasvir in combination with simepr)17.9(ev)]TJ
0 Tc 0 Tw (-)Tj
-0.01 Tc 0.066 Tw 0 -1.167 TD
[(ir \261 ribavirin for hepatitis C vir)8(us genotype 1 infection.)-10( )]TJ
0.248 Tw 0 -1.167 TD
[(In Pr)18(ogram and )37.2(Abstracts of the 21st Confer)18(ence on)-10( )]TJ
0.059 Tw T*
[(Retr)18(ovir)8(uses and Opportunistic Infections \(CROI 2014\),)-10( )]TJ
0 Tw 0 -1.167 TD
[(Boston, Mar)18(ch 3-6, 2014, )37(Abstract 28LB.)]TJ
0 Tc 0.184 Tw 0 -1.167 TD
[([16] Sulkowski M., Er)18(on J., W)50(yles D. TURQUOISE-I: )]TJ
0.125 Tw T*
[(safety and ef)18(ficacy of )36.7(ABT)55(-450/r/ombitasvir)74.1(, dasabu)]TJ
0 Tw (-)Tj
0.158 Tw 0 -1.167 TD
[(vir)74(, and ribavirin in patients co-infected with hepati)]TJ
0 Tw (-)Tj
0.063 Tw 0 -1.167 TD
[(tis C and HIV)74(-1. In Pr)18(ogram and )37.1(Abstracts of the 20th )]TJ
0.071 Tw T*
[(International AIDS )-37.3(Confer)18(ence. )-37.3(Melbourne, Australia, )]TJ
0 Tw 0 -1.167 TD
[(July 20-25, 2014, )37(Abstract MOAB0104LB.)]TJ
ET
endstream
endobj
33 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 510.4862 708.6614 cm
0 0 m
0 -28.346 l
S
Q
q 1 0 0 1 -581.1024 694.2382 cm
0 0 m
581.102 0 l
S
Q
q 1 0 0 1 0 694.2382 cm
0 0 m
581.102 0 l
S
Q
endstream
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 9 0 0 9 210.3218 697.6063 Tm
[(Spinal lesions by infectious spondylodiscitis and hepatocellular c)0.6(ar)18(cinoma)]TJ
ET
endstream
endobj
38 0 obj
<>
endobj
39 0 obj
<>
endobj
40 0 obj
<>stream
H\j0~
CIq&0rXcdf3ϟաr{'zg^[hxZg`vW 5u¡rݨ䃒)̰x*yC.*%$MBQŎ>f@Hb۪yE=G~-b7-]PFDP|J۹kLiJASd
3YjX0o̹pμ1̥p|>0'a:ѢSN-z4ѢG-z4ѢG-O
Y9z./`
endstream
endobj
41 0 obj
<>stream
HV Tw&+<$qgZ-ԮZR*"*"! @@ B%@C}tw}nU[%_?/,bX%^>>fbomZF&HmgNqdvO{Oh<.x>H59{O?Źq-wqt~h]uwss'daRS+ʔrRD䒘rZE*)M>KUT+"J"PFp:NSVWVIHTGRdk
@MIդ@*">?*<\,F'%JקR-ʬ0J2*V)VBX&U=
$kXȔZ@^>esHA,AKaȗ¬VB,zڞm_ 'p HX11cwr=i9t#YŘ@19c6)BF8!3:1cqBnS.W+,a::KʰU|f3ً5up@.?Mw_;{o:h-̠Ė3#r
x@ 3آrI\&zRcM&wUXP~(eqHx櫪x±]ExusvX+3f RY1ul)Q%,OX=^
iASh7Uʳ%'>n